Ropinirole Hydrochloride for ALS

Shinichi Takahashi, Satoru Morimoto, Komei Fukushima, Jin Nakahara, Hideyuki Okano

Research output: Contribution to journalArticle

Abstract

Our laboratory previously established spinal motor neurons (MN) from induced-pluripotent stem cells (iPSCs) prepared from both sporadic and familial ALS patients, and successfully recapitulated disease-specific pathophysiological processes. We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovered that ropinirole hydrochloride prevented MN death. In December 2018, we started an investigator-initiated clinical trial testing ropinirole hydrochloride extended-release tablets in ALS patients. This is an on-going phase I/IIa randomized, double-blind, placebo-controlled, single-center, open-label continuation clinical trial (UMIN000034954). The primary aim is to assess the safety and tolerability of ropinirole hydrochloride in patients with ALS. We will also perform an efficacy evaluation using patient-derived iPSCs/MN. Major inclusion criteria were as follows: 1) 'clinically possible and laboratory-supported ALS', 'clinically probable ALS' or 'clinically definite ALS', according to the criteria for the diagnosis of ALS (El Escorial revised) and within 60 months after disease onset; 2) change in ALSFRS-R score of -2 to -5 points during the 12-week run-in period. Finally, 15 patients will be assigned to the active drug and 5 patients to the placebo. Our trial will be a touchstone trial for iPSC-based drug development strategies.

Original languageEnglish
Pages (from-to)1279-1288
Number of pages10
JournalBrain and nerve = Shinkei kenkyu no shinpo
Volume71
Issue number11
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Induced Pluripotent Stem Cells
Motor Neurons
Pharmaceutical Preparations
Placebos
Clinical Trials
Tablets
ropinirole
Research Personnel
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ropinirole Hydrochloride for ALS. / Takahashi, Shinichi; Morimoto, Satoru; Fukushima, Komei; Nakahara, Jin; Okano, Hideyuki.

In: Brain and nerve = Shinkei kenkyu no shinpo, Vol. 71, No. 11, 01.11.2019, p. 1279-1288.

Research output: Contribution to journalArticle

Takahashi, Shinichi ; Morimoto, Satoru ; Fukushima, Komei ; Nakahara, Jin ; Okano, Hideyuki. / Ropinirole Hydrochloride for ALS. In: Brain and nerve = Shinkei kenkyu no shinpo. 2019 ; Vol. 71, No. 11. pp. 1279-1288.
@article{e84bee4f15c44f9d82b5b4dd649175d2,
title = "Ropinirole Hydrochloride for ALS",
abstract = "Our laboratory previously established spinal motor neurons (MN) from induced-pluripotent stem cells (iPSCs) prepared from both sporadic and familial ALS patients, and successfully recapitulated disease-specific pathophysiological processes. We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovered that ropinirole hydrochloride prevented MN death. In December 2018, we started an investigator-initiated clinical trial testing ropinirole hydrochloride extended-release tablets in ALS patients. This is an on-going phase I/IIa randomized, double-blind, placebo-controlled, single-center, open-label continuation clinical trial (UMIN000034954). The primary aim is to assess the safety and tolerability of ropinirole hydrochloride in patients with ALS. We will also perform an efficacy evaluation using patient-derived iPSCs/MN. Major inclusion criteria were as follows: 1) 'clinically possible and laboratory-supported ALS', 'clinically probable ALS' or 'clinically definite ALS', according to the criteria for the diagnosis of ALS (El Escorial revised) and within 60 months after disease onset; 2) change in ALSFRS-R score of -2 to -5 points during the 12-week run-in period. Finally, 15 patients will be assigned to the active drug and 5 patients to the placebo. Our trial will be a touchstone trial for iPSC-based drug development strategies.",
author = "Shinichi Takahashi and Satoru Morimoto and Komei Fukushima and Jin Nakahara and Hideyuki Okano",
year = "2019",
month = "11",
day = "1",
doi = "10.11477/mf.1416201438",
language = "English",
volume = "71",
pages = "1279--1288",
journal = "Brain and Nerve",
issn = "0006-8969",
publisher = "Igaku-Shoin Ltd",
number = "11",

}

TY - JOUR

T1 - Ropinirole Hydrochloride for ALS

AU - Takahashi, Shinichi

AU - Morimoto, Satoru

AU - Fukushima, Komei

AU - Nakahara, Jin

AU - Okano, Hideyuki

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Our laboratory previously established spinal motor neurons (MN) from induced-pluripotent stem cells (iPSCs) prepared from both sporadic and familial ALS patients, and successfully recapitulated disease-specific pathophysiological processes. We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovered that ropinirole hydrochloride prevented MN death. In December 2018, we started an investigator-initiated clinical trial testing ropinirole hydrochloride extended-release tablets in ALS patients. This is an on-going phase I/IIa randomized, double-blind, placebo-controlled, single-center, open-label continuation clinical trial (UMIN000034954). The primary aim is to assess the safety and tolerability of ropinirole hydrochloride in patients with ALS. We will also perform an efficacy evaluation using patient-derived iPSCs/MN. Major inclusion criteria were as follows: 1) 'clinically possible and laboratory-supported ALS', 'clinically probable ALS' or 'clinically definite ALS', according to the criteria for the diagnosis of ALS (El Escorial revised) and within 60 months after disease onset; 2) change in ALSFRS-R score of -2 to -5 points during the 12-week run-in period. Finally, 15 patients will be assigned to the active drug and 5 patients to the placebo. Our trial will be a touchstone trial for iPSC-based drug development strategies.

AB - Our laboratory previously established spinal motor neurons (MN) from induced-pluripotent stem cells (iPSCs) prepared from both sporadic and familial ALS patients, and successfully recapitulated disease-specific pathophysiological processes. We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovered that ropinirole hydrochloride prevented MN death. In December 2018, we started an investigator-initiated clinical trial testing ropinirole hydrochloride extended-release tablets in ALS patients. This is an on-going phase I/IIa randomized, double-blind, placebo-controlled, single-center, open-label continuation clinical trial (UMIN000034954). The primary aim is to assess the safety and tolerability of ropinirole hydrochloride in patients with ALS. We will also perform an efficacy evaluation using patient-derived iPSCs/MN. Major inclusion criteria were as follows: 1) 'clinically possible and laboratory-supported ALS', 'clinically probable ALS' or 'clinically definite ALS', according to the criteria for the diagnosis of ALS (El Escorial revised) and within 60 months after disease onset; 2) change in ALSFRS-R score of -2 to -5 points during the 12-week run-in period. Finally, 15 patients will be assigned to the active drug and 5 patients to the placebo. Our trial will be a touchstone trial for iPSC-based drug development strategies.

UR - http://www.scopus.com/inward/record.url?scp=85074960203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074960203&partnerID=8YFLogxK

U2 - 10.11477/mf.1416201438

DO - 10.11477/mf.1416201438

M3 - Article

C2 - 31722314

AN - SCOPUS:85074960203

VL - 71

SP - 1279

EP - 1288

JO - Brain and Nerve

JF - Brain and Nerve

SN - 0006-8969

IS - 11

ER -